Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol-Myers Squibb (BMY – Research Report) and Envista ...

David Risinger, an analyst from Leerink Partners, maintained the Hold rating on Bristol-Myers Squibb (BMY – Research Report). The associated price target was raised to $55.00. David Risinger has given ...

On Friday, Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $54.32 which represents a decrease of $-1.45 or -2.60% from the prior close of $55.77. The stock opened at $55.88 and ...

In a welcome move, Bristol Myers Squibb saw its Relative Strength Rating improve from 70 to 76 on Tuesday. Please watch the video at Investors.com - Stock Market Exposure: How To Make Incremental ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

A multidisciplinary team of experts in lung cancer screening and implementation science from the UCLA Health Jonsson Comprehensive Cancer Center, the David Geffen School of Medicine at UCLA and the ...

By Rishika Sadam and Kashish Tandon HYDERABAD/BENGALURU (Reuters) -Indian generic drugmaker Dr Reddy's Laboratories' second-quarter profit was hit by one-time charges related to its joint venture with ...

(Reuters) -Indian generic drugmaker Dr Reddy's Laboratories reported a second-quarter profit that missed analysts' expectations on Tuesday, weighed down by pricing pressure in a competitive North ...

Reports of drug-related supply-chain issues were 40 percent less likely to result in drug shortages in Canada versus the United States, according to a new study.

Squibb laughs good-naturedly. “I don’t think we did, but we got a lot of laughs,” she admits. She also cites a clip she saw ...